Is Neogen (NEOG) overvalued or fairly valued?

MarketChacha shows Neogen's valuation in context — a forward P/E of about 31.1, a price-to-book of about 1.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Neogen's revenue?

Neogen reported revenue of $870.4M for FY2026, with net profit of $-7.9M, per official filings.

What is the share price of Neogen (NEOG)?

Neogen last traded at $11.83 (+1.6% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Neogen

NEOG · NYSE · Healthcare · United States

Snapshot

TickerNEOG

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees2,636

HeadquartersLansing, United States

Websitewww.neogen.com

Filings tracked20

About Neogen

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns for food producers and processors. It also provides reagents and test kits used in immunoassay production, forensic and animal toxicology, and life science research; unique colorimetric and chemiluminescent substrates for research use; veterinary instruments and delivery systems used for administering antibiotics and vaccines under the Ideal and Prima Tech brands; and precision instruments designed for injections, topical and oral administration, artificial insemination, and animal identification for farmers, ranchers, and veterinarian under the Prima Tech brand. In addition, the company offers digestive aids and nutritional supplements; Natural Vitamin E-AD to address vitamin deficiencies in swine, cattle, and sheep; RenaKare; companion animal parasiticides under Provecta brand; BotVax B; EqStim; ImmunoRegulin, used in dogs to assist in managing pyoderma; companion animal parasiticides under the Provecta brand; rodent and insect control products under the Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard brands. Further, it markets Uniprim, a veterinary antibiotic; operates sgenomics labs offering DNA genotyping, sequencing, and trait analysis for livestock and companion animals; and provides software systems that help testers to analyze and store results and perform analysis on the results from multiple locations over extended periods. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

Who owns it

Insiders0.7%
Institutions99.3%
Public & other0.0%

408 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.15.33%
Neuberger Berman Group, LLC7.60%
Vanguard Portfolio Management LLC5.98%
Dimensional Fund Advisors LP4.51%
Vanguard Capital Management LLC4.43%
SG Americas Securities, LLC4.29%
T. Rowe Price Investment Management, Inc.4.28%
ING Groep N.V.4.17%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Latest ROE of -0.4% is on the low side — the business earns a modest return on shareholder capital.

Net margin trend-2.8% → -0.9%

Margin has expanded by about 1.9 points — the business is getting more profitable.

Return on equity-0.4%

Latest ROE of -0.4% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $228.6M · EPS 0.09

Est. earnings growth -6.7%

Next fiscal year

Rev $865.6M · EPS 0.38

Est. earnings growth +22.6%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2026)

$870.4M

Net margin

-0.9%

ROE

-0.4%

Revenue CAGR (3y)

+1.9%

EPS (FY2026)

-0.04

Net profit (FY2026)

$-7.9M

Ask MarketChacha about NEOG

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2026	$870.4M	$-7.9M	-0.04	-0.9%	-0.4%
FY2025	$894.7M	$-1.1B	-5.03	-122.1%	-52.7%
FY2024	$924.2M	$-9.4M	-0.04	-1.0%	-0.3%
FY2023	$822.4M	$-22.9M	-0.12	-2.8%	-0.7%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$211.2M	$-17.0M	-0.08	-8.0%
2025Q4	$224.7M	$-15.9M	-0.07	-7.1%
2025Q3	$209.2M	$36.3M	0.17	17.4%
2025Q1	$221.0M	$-10.9M	-0.05	-4.9%
2024Q4	$231.3M	$-456.3M	-2.10	-197.3%
2024Q3	$217.0M	$-12.6M	-0.06	-5.8%
2024Q1	$228.8M	$-2.0M	-0.01	-0.9%
2023Q4	$229.6M	$-3.5M	-0.02	-1.5%
2023Q3	$229.0M	$1.5M	0.01	0.7%
2023Q1	$218.3M	$8.2M	0.04	3.8%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change
SEC8/7/2026material
10-K filing
SEC7/30/2026
8-K — Results of operations, Exhibits
SEC7/30/2026material
8-K — Reg FD disclosure, Exhibits
SEC4/20/2026material
8-K — Results of operations, Exhibits
SEC4/9/2026material
10-Q filing
SEC4/9/2026
8-K — Executive/director change
SEC3/30/2026material
8-K — Results of operations, Exhibits
SEC1/8/2026material
10-Q filing
SEC1/8/2026

2025

8-K — Executive/director change, Other events, Exhibits
SEC10/30/2025material
8-K/A — Executive/director change, Exhibits
SEC10/28/2025
8-K — Shareholder vote results, Exhibits
SEC10/27/2025material
8-K/A — Shareholder vote results, Exhibits
SEC10/27/2025
8-K — Results of operations, Exhibits
SEC10/9/2025material
10-Q filing
SEC10/9/2025
8-K — Executive/director change, Other events, Exhibits
SEC9/15/2025material
8-K — Executive/director change, Exhibits
SEC8/21/2025material
8-K — Executive/director change, Other events, Exhibits
SEC8/14/2025material
10-K filing
SEC7/30/2025
8-K — Results of operations, Exhibits
SEC7/29/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.